Table 2.

Time from randomisation to negative PCR in the intention-to-treat population

		Molnupiravir (n=90)	Placebo (n=90)
Median time from randomisation to negative PCR (95% CI), days
All		8 (8–9)	11 (10–11)
Alpha (B.1.1.7)		11 (5–22); n=17	11 (11–15); n=20
EU1 (B.1.177)		8 (5–8); n=15	11 (8–15); n=13
Omicron (B.1.1.529) BA.1		8 (5–8); n=15	11 (5–14); n=12
Omicron (B.1.1.529) BA.2		8 (3–NE); n=5	15 (7–NE); n=6
Delta (B.1.617.2)		11 (8–12); n=37	10 (8–11); n=35
Proportion with negative PCR test
Day 15
	Actual number	77 (86%)	73 (81%)
	Kaplan–Meier estimate (95% CI)	86·5% (78·6–92·6)	84·2% (75·6–91·0)
Day 29
	Actual number	85 (94%)	79 (88%)
	Kaplan–Meier estimate (95% CI)	95·5% (89·7–98·5)	91·5% (84·3–96·2)

Data are n (%), unless otherwise specified. NE=not estimable.